ライフサイエンスコーパス: menopausal transition

1 conditions and diseases associated with the menopausal transition.

2 ge in menstrual bleeding patterns during the menopausal transition.

3 tiated within a 'critical window' during the menopausal transition.

4 ute to higher depressive symptoms during the menopausal transition.

5 with greater hot flash reporting during the menopausal transition.

6 but their incidence rises sharply after the menopausal transition.

7 Nation (SWAN), an observational study of the menopausal transition.

8 mood, memory and sleep that occur during the menopausal transition.

9 participating in a longitudinal study of the menopausal transition.

10 .4 mg/d) in attenuating bone loss during the menopausal transition.

11 eased frequency of VMS in migraineurs during menopausal transition.

12 sting that HIV blunts weight gain during the menopausal transition.

13 loss may be even greater for WWH during the menopausal transition.

14 quency of VMS but not vaginal dryness during menopausal transition.

15 ment-related symptoms, mostly related to the menopausal transition.

16 n increased frequency of VMS in women during menopausal transition.

17 nopausally, and are most pronounced over the menopausal transition.

18 energy homeostasis and bone loss during the menopausal transition(1,2).

19 tion (3.47 um/year, P = .002) and during the menopausal transition (9.41 um/year, P < .0001), but not

20 r symptoms per day; 52% of the women were in menopausal transition and 48% were postmenopausal.

21 Many questions about menopausal transition and its effects on health have not

22 Physical symptoms associated with the menopausal transition and mood changes seen during this

23 ential bias in the understanding of both the menopausal transition and the linkage between the transi

24 or women-early risk factor onset, pregnancy, menopausal transition, and so on.

25 During the menopausal transition, approximately 50% to 75% of women

26 During the menopausal transition, approximately 50% to 75% of women

27 hod to 4 alternative proposed markers of the menopausal transition are compared with previous finding

28 terations in serum hormone levels across the menopausal transition are linked to depressive symptoms.

29 Data on the menopausal transition are used to illustrate the problem

30 osis who were assessed longitudinally during menopausal transition as part of the Study of Women's He

31 h perceptions and QOL include experiencing a menopausal transition as part of therapy, and feeling mo

32 n with depressive syndromes during and after menopausal transition but associated with a higher risk

33 ligned with proposed bleeding markers of the menopausal transition, but for some women they are not c

34 menstrual period, sCD14 increased during the menopausal transition by 250.71 ng/mL per year (95% CI,

35 times more likely to occur during a woman's menopausal transition compared with when she was premeno

36 was 2(1/2) times more likely to occur in the menopausal transition compared with when the woman was p

37 e history of depression, those who enter the menopausal transition earlier have a significant risk fo

38 During the menopausal transition, endogenous oestradiol concentrati

39 ps based on menstrual characteristics of the menopausal transition experience.

40 strand transfer inhibitors (INSTIs) and the menopausal transition have been associated with body com

41 ss the Nation) is a prospective study of the menopausal transition in 3,302 minority (African America

42 The menopausal transition in human females, which is driven

43 The menopausal transition is a pivotal time of cardiovascula

44 sk of stroke during middle age than men, the menopausal transition is a time when many women develop

45 The menopausal transition is characterized by rapid bone los

46 al atherogenic shift overlapping the time of menopausal transition is observed.

47 The menopausal transition is significantly associated with a

48 Perimenopause, or the menopausal transition, is the few-year time period prece

49 gen concentrations decline by 60% during the menopausal transition, leading to a relative androgen ex

50 f decreasing estradiol concentrations during menopausal transition may explain the increased frequenc

51 relate to the distribution of the preceding menopausal transition (MT), when women begin to experien

52 Moreover, women undergoing the menopausal transition often complain of problems with me

53 ertain nutrients may influence the effect of menopausal transition on obesity in African American wom

54 ble clusters, how clusters change across the menopausal transition, or if distinct phenotypes are pre

55 cardiovascular changes that occur during the menopausal transition period and the role of ovarian age

56 The menopausal transition period spans, on average, 2-8 year

57 n criteria, most longitudinal studies of the menopausal transition probably include only a subset of

58 essants in depressive women during and after menopausal transition, PubMed, Cochrane Library, EMBASE

59 treatment, such as that commonly used in the menopausal transition, results in long-term increases in

60 pitulating fundamental features of the human menopausal transition, results of transcriptomic analysi

61 sclerosis and subclinical disease during the menopausal transition, thus delaying or preventing the o

62 heory invokes bioenergetic signatures of the menopausal transition to propose sex-specific diagnostic

63 ovascular risk reduction in women undergoing menopausal transition using the framework of the America

64 cal implications of immune activation during menopausal transition warrant further investigation.

65 In WWH, the menopausal transition was associated with BMI and WC tra

66 to the chronological age (40-44) suggesting menopausal transition, when both cycles and periods beco

67 study that evaluated proposed markers of the menopausal transition, where the markers are measures ba